Pol Hans

Superoxide anion scavenging effect and superoxide dismutase activity ofGinkgo biloba extract

Ginkgo biloba extract is known to be efficient in diseases associated with free radical generation. The purpose of this work was to study, under in vitro conditions, the action ofGinkgo biloba extract (Gbe) against superoxide anion (

Relative prognostic value of best motor response and brain stem reflexes in patients with severe head injury.

O_{2^{\bar .} }

Clinical and radiological aspects of dysplastic gangliocytoma (Lhermitte-Duclos disease): a report of two cases with review of the literature.

), which is directly or indirectly implicated in cell damage. Gbe appears to have both an

Propofol Protects Cultured Rat Hippocampal Neurons against N-Methyl-D-Aspartate Receptor-Mediated Glutamate Toxicity

O_{2^{\bar .} }

Increase in antioxidant capacity of plasma during propofol anesthesia

scavenging effect and also a superoxide dismutase activity. Its antiradical effect was demonstrated by low temperature electron spin resonance and in a non-enzymatic system (phenazine methosulfate-NADH), and its enzymatic activity was shown by polarographic determination.

Comparison of the Surgical Pleth Index™ with haemodynamic variables to assess nociception–anti-nociception balance during general anaesthesia

Background:Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This study explored the dose–response relation of sugammadex given as a reversal agent at reappearance of the second muscle twitch after rocuronium- and vecuronium-induced block. A secondary objective was to investigate the safety of single doses of sugammadex. Methods:In this two-center, phase II, dose-finding study, 80 patients (age ≥ 18 yr, American Society of Anesthesiologists physical status I or II, surgery ≥ 60 min requiring muscle relaxation for intubation) were randomly assigned to receive rocuronium (0.60 mg/kg) or vecuronium (0.10 mg/kg). Sugammadex or placebo was administered at reappearance of the second muscle twitch. The primary efficacy endpoint was time from starting sugammadex administration until recovery of the train-of-four ratio to 0.9. Results:Compared with placebo, sugammadex produced dose-dependent decreases in mean time to recovery for all train-of-four ratios in the rocuronium and vecuronium groups. The mean time for recovery of the train-of-four ratio to 0.9 in the rocuronium group was 31.8 min after placebo compared with 3.7 and 1.1 min after 0.5 and 4.0 mg/kg sugammadex, respectively. The mean time for recovery of the train-of-four ratio to 0.9 in the vecuronium group was 48.8 min after placebo, compared with 2.5 and 1.4 min after 1.0 and 8.0 mg/kg sugammadex, respectively. Sugammadex was well tolerated. Conclusion:Sugammadex rapidly reversed rocuronium- or vecuronium-induced neuromuscular block at reappearance of the second muscle twitch and was well tolerated. A dose–response relation was observed with sugammadex for reversal of both rocuronium- and vecuronium-induced neuromuscular block.